Navigation Links
Panacea Pharmaceuticals Announces the Availability of CC Detect(SM), a Serum-Based Diagnostic Test for Colon Cancer
Date:11/14/2007

GAITHERSBURG, Md., Nov. 14 /PRNewswire-FirstCall/ -- Panacea Pharmaceuticals, Inc. announced today that CC Detect(SM), the Company's serum- based colon cancer diagnostic test, is now available from Panacea Laboratories. CC Detect(SM) is a simple blood test that should facilitate the identification of individuals with cancer of the colon and rectum when used in conjunction with standard screening methods. Panacea Laboratories, a division of Panacea Pharmaceuticals, is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The blood sample can be ordered by any physician and sent to Panacea for testing; sample and shipping requirements are available at http://www.panacea-labs.com.

Colorectal cancer -- cancer of the colon or rectum -- is the third most common type of cancer diagnosed in the US. 153,760 new colorectal cancer cases and 52,180 deaths due to colorectal cancer are expected in 2007. In an effort to detect colorectal cancer in its earliest stages, The American Cancer Society (ACS) and similar organizations have published guidelines for colorectal screening. It is recommended that most people begin colorectal screening at age 50 and that this screening be repeated at specific time intervals. Approximately, 5-10% of all colorectal cancers occur in people who are at "high risk," defined as much greater than twice the average risk. An additional 15-20% of colorectal cancers occur in people at "increased risk," defined as approximately twice average risk. It is recommended that people at high and increased risk for colorectal cancer begin screening at a younger age and have screening repeated more frequently. Factors associated with an increased or high risk of colorectal cancer can be divided into two categories: personal, and hereditary or familial. Personal risk factors include: a history of colorectal cancer that has been completely removed and, to a lesser extent, a h
'/>"/>

SOURCE Panacea Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... ENT and Allergy Associates, LLP (ENTA) does ... opposite. , New York/New Jersey’s premier ear, nose, ... physicians offering superior healthcare to children and adults in ... New York area-only considers adding to its current footprint ... includes the right communities to serve, the right locations ...
(Date:6/18/2013)... June 18, 2013 Internationally acclaimed ... new website, thebestbreast.com, showcasing his unique approach to ... information about his surgical method and highlights the ... on his website, Dr. Tebbetts compares his breast ... methods, Dr. Tebbetts’ method does not necessitate the ...
(Date:6/18/2013)... Belleville, Ill. (PRWEB) June 18, 2013 More ... older are living with HIV/AIDS, according to the Centers for ... don’t know they are infected. In support of National HIV ... Social Security Disability Insurance (SSDI) representation, the CDC ... HIV testing. , The CDC reports about 50,000 new ...
(Date:6/18/2013)... Healthcare Solutions , the ... Management, today announced the appointment of Richard Leonardo ... this position, Leonardo will direct Healthcare Solutions’ national ... growth initiatives. , Recognized in the property and ... brings more than 20 years of experience in ...
(Date:6/18/2013)... New York, NY (PRWEB) June 18, 2013 ... Sinai Medical Center to its “Best Doctors” list, up ... in New York City. The new issue also lists 52 ... network, which continues on a strategic growth trajectory. The “Best ... physicians, appears in the June 24 print issue and is ...
Breaking Medicine News(10 mins):Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 2Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 3Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 4Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 5Health News:Internationally Acclaimed Breast Augmentation Expert Announces the Launch of His New Website 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3Health News:Healthcare Solutions Appoints Richard Leonardo to Chief Sales Officer 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 3
... hospitals in New York are having a nice holiday with ... program is called Clown Care and believes in the saying ... at New York-Presbyterian Hospital runs this program. It is a ... was introduced by Michael Christensen, co-founder of Big Apple Circus. ...
... of certain stomach drugs may weaken the bones in the ... a new study that advises doctors to consider the risk ... University of Pennsylvania Medical School studied records from the general ... aged over 50 and some had been taking proton pump ...
... At least two children have reportedly died from malnutrition ... //, emblematic of a deep-rooted problem afflicting over 80,000 ... Purushottam of Ateri village died Sunday, two-year-old Chhottu died ... to take special care of him, the activists said., ...
... study of the most widely used osteoporosis drug has found ... without increasing their fracture risk for as long as five ... researchers at the University of California, San Francisco. The research ... spine fractures might be better-off continuing treatment. ,"This ...
... Patna Medical College and Hospital (PMCH) Monday as junior ... despite assurances from the Bihar government. ,The doctors ... on some of them by attendants of a patient. ... assurance to fulfil their demands, Vinod Kumar, one of ...
... switch, the hepatitis C virus turns on human immune ... those defenses by manipulating interaction of key cellular proteins, ... same molecular “on/off switch” controls immunity against many viruses, ... fight viruses, the researchers report. ,In a ...
Cached Medicine News:Health News:Malnutrition Kills Two Kids In Madhya Pradesh 2Health News:Women Faces No Risk on Discontinuation of Osteoporosis Drug 2Health News:Women Faces No Risk on Discontinuation of Osteoporosis Drug 3Health News:Molecular ‘On/Off Switch’ Controls Immune Defenses Against Virus 2
(Date:6/18/2013)... June 18, 2013 Decision Resources, one of the ... issues, finds that, over the past 12 months, 25 percent ... , Germany , Italy ... United Kingdom ) have been required to change the ... patients, primarily to reduce costs. Additionally, more than 40 percent ...
(Date:6/18/2013)... NEW YORK , June 18, 2013 /PRNewswire/ ... BDX ) are accelerating the development of new products ... through a new collaboration announced today. This new, three-year commitment ... 1 diabetes (T1D). Many patients with T1D not ... a catheter to be placed in the body for a ...
(Date:6/18/2013)... , June 18, 2013 Today, ... Inc. (NASDAQ: GILD ), Health Management Associates Inc. ... IDXX ), ISIS Pharmaceuticals Inc. (NASDAQ: ISIS ... access these reports free of charge - including full price ... below. Gilead Sciences, Inc. Research Report ...
Breaking Medicine Technology:One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 2One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 3JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 2JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6
... for Perforomist(TM) (Formoterol Fumarate) Inhalation ... International ATS Conference --, NAPA, Calif., May ... of the American Thoracic Society (ATS) demonstrate,that concomitant ... FFIS), delivered by nebulization,and Spiriva(R) (tiotropium; TIO) is ...
... be Extended if Patients Receive the ... Most Effective Treatment Identified by ChemoFx, CHICAGO, May ... Assay, a cell-based test that examines the,response of a ... overall survival (OS) in patients with,primary ovarian cancer. Patients ...
Cached Medicine Technology:Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 2Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 3Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 4Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 5Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 6Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer 2Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer 3
Indications For Usage: ,Laser surgery of the larynx or other areas in close proximity to the tracheal tube using CO2 or KTP laser beam....
Indications For Usage: ,Airway management during pediatric surgical procedures and intensive care....
... The Thermal Angel® is an in-line, ... and IV fluid warming device, capable of ... Thermal Angel® can be used to help ... TA-200 will strive to achieve 38°C (100.4°F) ...
Futuremeds Astotherm Plus Blood and Fluid Warmers meet American Blood Bank and ECRI standards., ,Astotherm is a durable warmer you can rely on for many years....
Medicine Products: